Hematide peginesatide regulatory update

Affymax and partner Takeda said they plan to submit an NDA for Hematide peginesatide to treat anemia in chronic kidney disease (CKD) in dialysis patients in 1H11. The timeline will be finalized following a meeting with FDA that is expected to be held by year end. The companies will continue to evaluate the synthetic peptide-based erythropoiesis-stimulating agent (ESA) in non-dialysis patients. ...